While there are currently no PPARδ agonists in clinical use, promising studies in animals have demonstrated that activating PPARδ has beneficial effects on obesity, hypercholesterolemia, insulin resistance, and exercise endurance (20, 21). The gene discussed is PPARD; the disease is Obesity.